{"nctId":"NCT04058366","briefTitle":"Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy","startDateStruct":{"date":"2019-12-05","type":"ACTUAL"},"conditions":["Cystic Fibrosis"],"count":251,"armGroups":[{"label":"ELX/TEZ/IVA","type":"EXPERIMENTAL","interventionNames":["Drug: ELX/TEZ/IVA","Drug: IVA"]}],"interventions":[{"name":"ELX/TEZ/IVA","otherNames":["VX-445/VX-661/VX-770","elexacaftor/tezacaftor/ivacaftor"]},{"name":"IVA","otherNames":["VX-770","ivacaftor"]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Completed study drug treatment in parent study (VX18-445-104); or had study drug interruption(s) in parent study but completed study visits up to the last scheduled visit of the Treatment Period in the parent study\n\nKey Exclusion Criteria:\n\n* History of study drug intolerance in parent study\n\nOther protocol defined Inclusion/Exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Part A: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"241","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null}]}]}]},{"type":"SECONDARY","title":"Part A: Absolute Change From Parent Study Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)","description":"FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Part A: Absolute Change From Parent Study Baseline in Sweat Chloride (SwCl)","description":"Sweat samples were collected using an approved collection device.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-23.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-22.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Part A: Absolute Change From Parent Study Baseline in Body Mass Index (BMI)","description":"BMI was defined as weight in kilogram (kg) divided by height in square meter (m\\^2).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.83","spread":null}]}]}]},{"type":"SECONDARY","title":"Part A: Absolute Change From Parent Study Baseline in BMI Z-score","description":"BMI was defined as weight in kilogram (kg) divided by squared height in meters (m\\^2). The z-score is a statistical measure to describe whether a value was above or below the standard. A z-score of 0 is equal to the standard. Lower numbers indicate values lower than the standard and higher numbers indicate values higher than the standard.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.40","spread":null}]}]}]},{"type":"SECONDARY","title":"Part A: Absolute Change From Parent Study Baseline in Body Weight","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Part A: Absolute Change From Parent Study Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score","description":"The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":38,"n":251},"commonTop":["Infective pulmonary exacerbation of cystic fibrosis","Headache","Cough","COVID-19","Diarrhoea"]}}}